[{"id":"8f37731b-089c-47c1-a812-0b453cccb247","acronym":"DENIVOS","url":"https://clinicaltrials.gov/study/NCT03669523","created_at":"2021-01-18T18:00:15.676Z","updated_at":"2025-02-25T15:10:56.744Z","phase":"Phase 2","brief_title":"Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)","source_id_and_acronym":"NCT03669523 - DENIVOS","lead_sponsor":"Centre Hospitalier Annecy Genevois","biomarkers":" EGFR • PD-L1 • BRAF • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 10/19/2023","primary_completion_date":" 10/19/2023","study_txt":" Completion: 10/19/2023","study_completion_date":" 10/19/2023","last_update_posted":"2025-02-13"},{"id":"65af3a39-ef1d-49dc-a8f5-a6e260b5808e","acronym":"PEACE-1","url":"https://clinicaltrials.gov/study/NCT01957436","created_at":"2021-01-18T08:53:11.774Z","updated_at":"2024-07-02T16:35:29.880Z","phase":"Phase 3","brief_title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","source_id_and_acronym":"NCT01957436 - PEACE-1","lead_sponsor":"UNICANCER","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • zoledronic acid"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1173","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2023-11-08"},{"id":"5e4173a0-f1b6-45fa-9023-3e3fc9e7ede2","acronym":"YAPPETIZER","url":"https://clinicaltrials.gov/study/NCT03358017","created_at":"2021-01-18T16:34:31.703Z","updated_at":"2024-07-02T16:35:32.529Z","phase":"Phase 2","brief_title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT03358017 - YAPPETIZER","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2 • TP53 • PGR • BRCA • TAFAZZIN","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • TP53 • PGR • BRCA • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 07/25/2023","study_completion_date":" 07/25/2023","last_update_posted":"2023-10-19"},{"id":"2697ccff-3b70-4de9-a777-812b3d98f80b","acronym":"ABCSG-18","url":"https://clinicaltrials.gov/study/NCT00556374","created_at":"2021-01-18T02:01:40.862Z","updated_at":"2024-07-02T16:35:41.885Z","phase":"Phase 3","brief_title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT00556374 - ABCSG-18","lead_sponsor":"Amgen","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 3420","initiation":"Initiation: 12/18/2006","start_date":" 12/18/2006","primary_txt":" Primary completion: 10/07/2014","primary_completion_date":" 10/07/2014","study_txt":" Completion: 07/26/2022","study_completion_date":" 07/26/2022","last_update_posted":"2023-07-27"},{"id":"69a6fb49-a8b9-43df-9af8-05036660346a","acronym":"HOBOE","url":"https://clinicaltrials.gov/study/NCT00412022","created_at":"2021-01-18T01:26:47.797Z","updated_at":"2024-07-02T16:35:52.374Z","phase":"Phase 3","brief_title":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.","source_id_and_acronym":"NCT00412022 - HOBOE","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • triptorelin • zoledronic acid"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1294","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-03-24"},{"id":"d2690b1d-65e0-4c96-b9ca-3b3247994b3e","acronym":"METZOLIMOS","url":"https://clinicaltrials.gov/study/NCT02517918","created_at":"2021-01-18T12:10:03.624Z","updated_at":"2024-07-02T16:35:59.884Z","phase":"Phase 1","brief_title":"Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma","source_id_and_acronym":"NCT02517918 - METZOLIMOS","lead_sponsor":"Institut Bergonié","biomarkers":" CD8 • CD4 • IL2 • TGFB1","pipe":"","alterations":" ","tags":["CD8 • CD4 • IL2 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • zoledronic acid • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/05/2016","primary_completion_date":" 09/05/2016","study_txt":" Completion: 11/16/2021","study_completion_date":" 11/16/2021","last_update_posted":"2022-11-29"},{"id":"cc62689a-9210-4497-9d99-6a97e2c2429c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00566618","created_at":"2021-01-18T02:04:00.307Z","updated_at":"2025-02-25T14:25:22.607Z","phase":"Phase 1/2","brief_title":"Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis","source_id_and_acronym":"NCT00566618","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 11/17/2020","primary_completion_date":" 11/17/2020","study_txt":" Completion: 11/17/2020","study_completion_date":" 11/17/2020","last_update_posted":"2022-02-25"},{"id":"8f50e9b1-ff0c-4afd-a3ec-80122b68a4d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164952","created_at":"2021-12-21T15:53:30.757Z","updated_at":"2024-07-02T16:36:19.303Z","phase":"Phase 3","brief_title":"Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole","source_id_and_acronym":"NCT05164952","lead_sponsor":"Assiut University","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2021-12-21"},{"id":"88a55a61-38e3-4292-be29-cd8c332d6d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951586","created_at":"2021-10-25T18:54:29.396Z","updated_at":"2024-07-02T16:36:22.500Z","phase":"Phase 2","brief_title":"Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01951586","lead_sponsor":"Amgen","biomarkers":" TNFRSF11A • TNFSF11","pipe":"","alterations":" ","tags":["TNFRSF11A • TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 226","initiation":"Initiation: 12/31/2013","start_date":" 12/31/2013","primary_txt":" Primary completion: 07/29/2016","primary_completion_date":" 07/29/2016","study_txt":" Completion: 11/28/2017","study_completion_date":" 11/28/2017","last_update_posted":"2021-10-25"},{"id":"1351f523-36c8-40f9-bb90-b10356338d46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04045522","created_at":"2021-01-18T19:50:16.442Z","updated_at":"2024-07-02T16:36:27.655Z","phase":"","brief_title":"Study on Bisphosphonates Targeting Triple-negative Breast Cancer","source_id_and_acronym":"NCT04045522","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2021-07-20"},{"id":"0999bd9c-b44a-412c-8986-522b58c74f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04325776","created_at":"2021-01-18T20:57:17.503Z","updated_at":"2024-07-02T16:36:40.172Z","phase":"Phase 2","brief_title":"A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis","source_id_and_acronym":"NCT04325776","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • ALK • MET • KIT • FGFR","pipe":"","alterations":" ","tags":["EGFR • ALK • MET • KIT • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • AL2846"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2020-10-12"},{"id":"2c13ee0a-6026-4fbc-beb7-3db069f73fe2","acronym":"NEO-ZOTAC","url":"https://clinicaltrials.gov/study/NCT01099436","created_at":"2021-01-18T04:20:55.612Z","updated_at":"2025-02-25T15:50:59.853Z","phase":"Phase 3","brief_title":"Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients","source_id_and_acronym":"NCT01099436 - NEO-ZOTAC","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2020-01-21"},{"id":"c34a35a5-32f3-4d5e-8a43-5cb81135448b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01671774","created_at":"2021-03-09T08:55:20.043Z","updated_at":"2024-07-02T16:36:54.467Z","phase":"Phase 1","brief_title":"Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer","source_id_and_acronym":"NCT01671774","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 10/16/2012","start_date":" 10/16/2012","primary_txt":" Primary completion: 10/13/2014","primary_completion_date":" 10/13/2014","study_txt":" Completion: 10/13/2014","study_completion_date":" 10/13/2014","last_update_posted":"2019-10-18"},{"id":"83457aae-a1ca-404f-b151-9dfae99c568a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02274623","created_at":"2022-01-21T19:53:41.049Z","updated_at":"2024-07-02T16:36:55.111Z","phase":"Phase 1","brief_title":"Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid","source_id_and_acronym":"NCT02274623","lead_sponsor":"OPKO Health, Inc.","biomarkers":" TAP1","pipe":"","alterations":" ","tags":["TAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 02/27/2017","primary_completion_date":" 02/27/2017","study_txt":" Completion: 03/17/2017","study_completion_date":" 03/17/2017","last_update_posted":"2019-09-27"},{"id":"48626291-e00b-4fdb-b9cb-b63fcd4aa449","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436917","created_at":"2021-01-18T01:32:33.333Z","updated_at":"2024-07-02T16:36:55.788Z","phase":"","brief_title":"Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer","source_id_and_acronym":"NCT00436917","lead_sponsor":"Mayo Clinic","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 05/09/2016","study_completion_date":" 05/09/2016","last_update_posted":"2019-09-11"},{"id":"7a73dccc-9d32-4819-ad4d-1d2be356e9d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194440","created_at":"2021-01-18T04:46:49.510Z","updated_at":"2024-07-02T16:37:06.996Z","phase":"Phase 2","brief_title":"Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms","source_id_and_acronym":"NCT01194440","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2018-09-12"},{"id":"0e0af965-9019-4216-8632-a165e17947c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01204203","created_at":"2021-01-18T04:49:32.600Z","updated_at":"2025-02-25T15:51:21.743Z","phase":"Phase 2","brief_title":"Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)","source_id_and_acronym":"NCT01204203","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2017-05-24"},{"id":"29044d41-44f8-4fb8-8597-f8b5331836e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472146","created_at":"2021-01-18T06:08:19.779Z","updated_at":"2024-07-02T16:37:22.665Z","phase":"Phase 2","brief_title":"ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer","source_id_and_acronym":"NCT01472146","lead_sponsor":"Susanne Crocamo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • doxorubicin hydrochloride • cyclophosphamide • zoledronic acid • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2017-05-09"},{"id":"4e2b0caf-43a6-4ba6-a703-c57392fe8679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00107263","created_at":"2021-01-18T00:20:58.936Z","updated_at":"2024-07-02T16:37:27.247Z","phase":"Phase 3","brief_title":"Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer","source_id_and_acronym":"NCT00107263","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 558","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 03/01/2007","primary_completion_date":" 03/01/2007","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2016-12-06"}]